Liver

Rheumatic Disease eJournal Club

IL-6 Receptor Inhibition with
Tocilizumab Improves Treatment
Outcomes in Patients with Rheumatoid Arthritis Refractory to Anti-TNF Biologics: Results from a 24-week Multicentre Randomised Placebo Controlled Trial

Publication: Emery P et al. Ann Rheum Dis. Published online June 2008

Print this Content

 

Release Date: October 9, 2008
Renewal Date:  October 9, 2009
Expiration Date: October 9, 2010

 

 

How to Obtain AMA PRA
Category 1 Credit™

  1. Read the provided journal article and slides.
  2. Listen to the
    audio discussion.
  3. Login to your account.
  4. Complete the registration / evaluation form.
  5. Print your personalized
    CME certificate.

Technical Requirements

 

Estimated Time of Completion: 45 minutes

Description
The purpose of activity is to review the safety and efficacy data from RADIATE, a randomized, placebo-controlled trial of tocilizumab in patients with RA who exhibited an inadequate response to one or more tumor necrosis factor inhibitors.

Objectives
On completion of this activity, participants should be able to:

  1. Outline the study design of RADIATE.
  2. Compare and contrast the American College of Rheumatology responses by visit for the placebo- and tocilizumab-treated groups.
  3. Describe the adverse events reported in the placebo and tocilizumab groups.

Target Audience
This activity is directed to physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in RA.

Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity may be submitted for American Osteopathic Association Continuing Medical Education credit in Category 2.

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio

Faculty

Paul Emery, MA, MD, FRCP
Professor, Academic Section of Musculoskeletal Disease
University of Leeds
Clinical Director, Department of Rheumatology
Leeds Teaching Hospitals
NHS Trust, Leeds, England

Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty has indicated that he may have a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:

Leonard Calabrese, DO
  Consulting: Abbott Laboratories; Genentech, Inc.; Roche Laboratories, Inc.
 
  Teaching and Speaking: Genentech, Inc.
 
Paul Emery, MA, MD, FRCP
  Consulting: F Hoffmann-La Roche, Ltd.
 
  Teaching and Speaking: Chugai Pharma KK;
F Hoffmann-La Roche, Ltd.

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges an educational grant for support of this activity from:

Roche Laboratories, Inc.

This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and DIME .

CME Disclaimer